【レポートの概要（一部）】
1. Report Overview
1.1 Overview of the World Market for Macular Degeneration and Other Retinal Diseases
1.2 Why You Should Read This Report
1.3 How This Report Delivers
1.4 Main Questions Answered by This Analysis
1.5 Who Is This Study For?
1.6 Methods of Research and Analysis
1.7 Frequently Asked Questions (FAQs)
1.8 Some Associated Reports
1.9 About Visiongain
2. World AMD and Other Disease Market, 2015
2.1 What are Retinal Diseases?
2.2 Types of Retinal Diseases
2.3 Diagnostics and Treatments for AMD and Other Retinal Diseases
2.4 Nearly 200 Million People with AMD?
2.5 Over 100 Million with DR
2.6 First RVO Estimates Suggest Patient Population of 16 Million
2.7 Market to Make Rapid Pace to 2026
2.8 Eylea Became Leading drug in the Market
2.9 Regeneron the Leading Presence in the Market
2.10 Which are the Most Significant Disease Areas for the Market?
3. Retinal Disease Market Subsectors, 2015
3.1 Wet AMD Still the Main Source of Revenue in the Market
3.2 Wet AMD: Angiogenic Processes Offer Well-Defined Drug Targets
3.2.1 Revenue Forecasting for Wet AMD segment, 2015-2026
3.3 Dry AMD: Unmet Need to Arrest or Reverse Damage to RPE
3.3.1 Dry AMD Segment to Emerge in the Forecast Period
3.4 DR: Coming Into Clinical Focus, with DME the Main Target
3.4.1 Segment to Grow in Importance as Diabetes Epidemic Continues
3.5 Lucentis and Eylea Label Extensions Highlight Possibilities in Other Disease Areas
3.6 Projections for All Segments, 2015-2026
4. Approved Products in the AMD and Other Retinal Diseases Market, 2015-2026
4.1 Will the Current Products Dominate the Market Through 2026?
4.2 Lucentis: Second Leading Drug in the Market
4.2.1 Positive Revenue Growth Shown in Past: 2012-2015
4.2.2 Shadow of Avastin Still Hangs Over Lucentis
4.2.3 CATT Study Results: Clinical Differences Still Have Yet to Emerge
4.2.4 Eylea: The Bigger Threat to Lucentis? (might shift in eylea section)
4.2.5 Extending the Label, Widening the Battleground: Lucentis Moves Into DME and Beyond
4.2.6 Improving Cost and Compliance for Lucentis
4.2.7 Lucentis Revenue Forecast 2015-2026
4.2.8 Will Loss of Physician Goodwill Harm Lucentis’ Growth?
4.3 Eylea: Holds the Throne?
4.3.1 Increasing Revenue Growth in Past: Outside US Sale Amplified
4.3.2 VIEW 1 and VIEW 2: Is Eylea Superior or Just Non-Inferior to Lucentis?
4.3.3 First Wave of Eylea’s Expansion Finally Beginning to Break?
4.3.4 Eylea into DME and Other New Indications
4.3.5 Eylea Revenue Forecast 2015-2026
4.3.6 How Far Can Eylea’s Momentum Carry It?
4.4 Avastin: No Formal wAMD Approval but Still the Most-Used Product
4.4.1 Past Revenue illustrates Increasing Use of Avastin for wetAMD
4.4.2 Judicial Review Averted in the UK by Price Adjustment
4.4.3 Multiple Attempts to Block Off-Label Avastin Since 2007
4.4.4 Roche and Novartis Challenge CATT’s Headline Conclusions
4.4.5 Will Eylea/Zaltrap Affect Avastin’s Place in the Market?
4.4.6 Avastin Revenue Forecast, 2015-2026
4.4.7 Will Anything Dislodge Avastin from its Central Position?
4.5 Visudyne (Valeant/Novartis): Declining Sales throughout the Forecast Period
4.5.1 Visudyne Revenue Forecast, 2015-2026
4.6 Jetrea (ThromboGenics/Novartis): Disappointing Launch in 2013
4.6.1 Jetrea Revenue Forecast, 2015-2026
5. Pipeline for Wet AMD Segment, 2015-2026
5.1 The Leading Pipeline Candidates
5.2 Fovista (Ophthotech Corporation/Novartis): The Next Big Thing?
5.2.1 Three Phase 3 Trials to Confirm Fovista’s Outstanding Phase 2 Results
5.2.2 Ophthotech Goes Public to Fund Phase 3 Effort
5.2.3 Ophthotech Partners with Novartis for Fovista
5.2.4 Improving Angiogenesis Inhibition by Blocking Pericyte Recruitment
5.2.5 The Move toward Combination Therapies
5.3 Other Growth Factor Targets in the Pipeline
5.3.1 Squalamine (OHR Pharmaceutical): Combination Targeting in a Single Eyedrop
5.3.2 Allergan and Molecular Partners: Preclinical DARPin Hits VEGF and PDGF
5.3.3 NT-506 (Neurotech Pharmaceutical): Sustained-Release VEGF/PDGF Options
5.3.4 iSONEP (Lpath): Pfizer Interested in Anti-S1P Monoclonal Antibody
5.4 Conbercept (Chengdu Kanghong Biotech): The Other Phase 3 Candidate in wAMD
5.4.1 A Chinese Competitor: Where Will Conbercept Fit In?
5.4.2 Binding Affinity Comparable to Eylea
5.5 Do We Need New Anti-VEGFR Agents or Delivery Systems?
5.5.1 Abicipar Pegol (Allergan): Novel Protein with Extended Half-Life
5.5.2 Brolucizumab (Alcon): Single-Chain Monoclonal Antibody Fragment
5.5.3 PDS 1.0 (ForSight Vision4): A New Option for Lucentis Delivery
5.5.4 NT-503 (Neurotech): New Delivery Platform for Anti-VEGF Agent
5.5.5 Pan-90806 (PanOptica): Anti-VEGF Eyedrop in Preclinical Development
5.5.6 Iontophoretic Delivery: EyeGate Pharmaceuticals Leading the Way
5.6 Novel Delivery Systems to Rejuvenate Anti-Inflammatory Approaches
5.6.1 Verisome System and IBI-30089 (Icon Bioscience)
5.6.2 CPC-551 (Colby Pharmaceutical): An Alternative Anti-Inflammatory Approach?
5.7 Other Targets Under Investigation in wAMD Drug Development
5.7.1 Are Kinase Inhibitors Still a Going Concern in wAMD?
5.7.2 Pazopanib (GlaxoSmithKline) and TG100801 (Sanofi): Two Eyedrop Kinase Inhibitors Drop Out of the Running
5.7.3 X-82 Pill (Tyrogenex): Dual Kinase Inhibitor
5.7.4 Factor C5: A More Promising Target Addressed by Zimura (Ophthotech) and LFG316 (Novartis)
5.7.5 Integrins: Another Blockable Component of the Neovascularisation Cascade?
5.7.6 Luminate (Allegro Ophthalmics): Novel Anti-Integrin Oligopeptide
5.7.7 Jetrea (ThromboGenics/Novartis): Can Pharmacologic Vitreolysis Help wAMD Patients?
5.7.8 Novel Anti-Angiogenic Treatments in Development: Ora Bio’s ORA102 and CoMentis’ ATG003
5.7.9 Zybrestat (Oxigene): New Mechanism of Action Offers Way to Disrupt Neovascularisation
5.7.10 Synthetic Biologies: Oligonucleotides and SiRNAs for wAMD
5.8 Regenerative Medicine Approaches
5.8.1 Allogeneic Stem Cells (Mesoblast): Potential Synergistic Treatment for Use alongside Lucentis
5.8.2 AVA-101 and AVA-201(Avalanche Biotechnologies): Ocular BioFactory for wAMD
5.8.3 RetinoStat (Oxford BioMedica): LentiVector Technology to Deliver Anti-Angiogenic Genes
6. Pipeline for Dry AMD Segment, 2015-2026
6.1 Who Will Achieve the Big Breakthrough in Dry AMD?
6.2 MC-1101 (MacuCLEAR): Leading the Pack?
6.2.1 Increasing Choroidal Blood Flow with Repurposed Product
6.2.2 Novel Endpoints in Phase 3 Study
6.2.3 Can MacuCLEAR Make It?
6.3 ACU-4429 (Acucela): Visual Cycle Modulator in Phase 3
6.3.1 Data Expected in July 2016
6.3.2 Other Visual Cycle Modulators
6.4 High Hopes for Complement Inhibition in Dry AMD
6.4.1 Lampalizumab (Roche): The Big News of ARVO 2013
6.4.2 MAHALO Study Indicates GA Progression Slowed by Lampalizumab
6.5 Corticosteroids: Targeting Inflammation’s Role in Dry AMD Pathogenesis
6.5.1 Iluvien (Alimera Sciences): Study terminated
6.5.2 AGN208397 (Allergan): New Potent Steroid Expected to Undergo Trials in Dry AMD
6.6 Neuroprotection: One of Modern Medicine’s Holy Grails
6.6.1 Tandospirone (Alcon): Not effective in GA
6.6.2 Renexsus (Neurotech): Possibly Promising Data in Dry AMD Studies
6.6.3 Novadur (Allergan): Possible Efficacy with Longer Duration of Action
6.6.4 VAR10200 (Varinel): A Preclinical Candidate to Watch
6.7 Regenerative Medicine: Dry AMD One of the Biggest Disease Targets
6.7.1 MA09-hRPE Cellular Therapy (Ocata Therapeutics): Signs of Efficacy in Landmark ESC Human Trial
6.7.2 HuCNS-SC (StemCells): Leading Company in Neural Stem Cell Space
6.7.3 Stemedyne-RPE (Stemedica Cell Technologies): Low-Oxygen Cells for Dry AMD Repair
6.7.4 OpRegen (Biotime): Stem Cell leader with Dry AMD Interests
6.7.5 First iPSC Trial in Japan in Dry AMD Patients
6.7.6 Gene Therapies Less Prominent Than Stem Cells in Dry AMD
6.8 Other Treatments for Dry AMD
7. Pipeline for Diabetic Retinopathy Segment, 2015-2026
7.1 Ozurdex/Posurdex (Allergan): Approved for General DME Patient Population
7.2 Lucentis: The Game Changer for DR?
7.3 New Anti-VEGF Additions
7.3.1 Is Eylea Better than Lucentis and Avastin for DME?
7.4 Steroids in Development for DR
7.4.1 Iluvien (Alimera/pSivida): New Option in European Markets
7.4.2 A New Hope? Optina (Ampio Pharmaceuticals)
7.4.3 Betamethasone Microsphere (Santen): Late-Stage Steroid Candidate
7.4.4 Cortiject (Santen): Prodrug Candidate
7.4.5 IBI-20089 (Icon Bioscience): Sustained-Release Formulation of Triamcinolone Acetonide
7.5 Other Products in Development for DR
7.5.1 Angiotensin Receptor Blockers/Angiotensin-Converting Enzyme Inhibitors: Some Off-Label Validation
7.5.2 Vitreosolve (Innovations in Sight): Will a Phase 3 Trial Be Initiated?
7.5.3 TriLipix (Abbott): No New Development for Promising Drug
7.5.4 iCo-007 Intravitreal Injection (iCo Therapeutics): Phase 2 Enrolment Completed June 2013
7.5.5 Jetrea (ThromboGenics/Novartis): Possibilities in DME?
8. Regional Market Breakdown, 2015-2026
8.1 Which Markets Hold the Most Revenue Growth Potential?
8.2 The US: Leading Market for Retinal Diseases
8.3 Japan: Strong Market Potential
8.4 EU5: Ageing Populations to Drive Market Growth
8.5 BRIC Nations: The Biggest Growth Driver for the Market
9. Qualitative Industry and Market Analysis, 2016-2026
9.1 Strengths: The Most Dynamic Area of the Ophthalmics Market
9.2 Weaknesses: Heavily Dependent on Anti-VEGF Approach
9.3 Opportunities: New Markets and R&D Synergies
9.4 Threats: Prevention and Management Better Than Drug Treatment for Dry AMD and DR?
9.5 Social: Low Diagnosis, Low Compliance
9.6 Technological: Innovation for the Eye
9.7 Economic: Off-Label Treatment and Reimbursement Issues
9.8 Political: The Demography and Diabetes Challenges
10. Research Interviews
10.1 Interview with Dr. Leigh J. Hsu, Vice President, Corporate Development & Strategy, Lpath, Inc.
10.1.1 Major Changes in AMD and Other Retinal Diseases Market
10.1.2 The Landscape of Emerging Markets
10.1.3 Opportunities and Plans of Marken’s Network
10.1.4 DR Market Opportunities
10.2 Interview with Philip G. Ralston, Jr., MacuCLEAR
10.2.1 MC-1101: Progress in Clinical Trials
10.2.2 MC-1101 More Effective in Early to Mid-Range AMD
10.2.3 Partnerships and Expected Launch of MC-1101
11. Report Conclusions
11.1 The Age of Lucentis: Nearing Its Conclusion?
11.2 Lucentis vs. Eylea vs. Avastin: The Three-Way Anti-VEGF Market
11.3 Indications Outside Wet AMD to Gain in Importance
11.4 Dry AMD Market Has Huge Potential
11.5 Fovista Most Prominent Among the Pipeline Candidates
11.6 Retinal Diseases to Continue to Be the Leading Area of Ophthalmics
Associated Visiongain Reports
Visiongain Report Sales Order Form
About Visiongain
Report Evaluation Form
【レポート販売概要】
■ タイトル：黄斑変性症（AMD）及びその他の網膜疾患治療薬の世界市場■ 英文：Macular Degeneration (AMD) and Other Retinal Diseases: World Drug Industry and Market 2016-2026
■ 発行日：2016年2月
■ 調査会社：visiongain
■ 商品コード：VGAIN6041528
■ 調査対象地域：グローバル
- セキュリティカメラ（赤外線イルミネーター）の世界市場予測（～2020）The Security Cameras (IR Illuminator) market is expected to grow from USD 1.75 Billion in 2015 to USD 2.68 Billion at a CAGR of 8.8%. The base year for study is 2014 and forecast is provided for the period of 2015 to 2020. Security issues in developing countries, reduction in ASP for IP cameras, acceptance of IR illumination for better vision are the major causes of growth in Security Cameras (IR …
- 過硫酸塩の世界市場：過硫酸アンモニウム、過硫酸ナトリウム、過硫酸カリウムPersulfates are inorganic compounds that are highly soluble in water. Persulfates are prepared by the electrolysis of their corresponding sulfates at low temperature and high current density. Decomposition is promoted by water and heat. Dissolving a persulfate in water yields an acidic solution due to oxidation of water. Persulfates are strong oxidants with a moderate shelf-life when they are stor …
- スキンケア化粧品の世界市場2019-2023About this market In recent years, the population in the age group of 30-45 years has been increasing worldwide. This is leading to growing demand for cosmetic skincare products to achieve flawless looking skin while improving the person’s overall appearance. The aging anxiety, environmental factors, concerns about changes in facial appearance, and the need to look younger have all led middle-aged …
- 配電フィーダー自動化システムの世界市場This report estimates the distribution feeder automation system market, in terms of revenue. The market has been segmented into application (commercial, industrial, & residential), product (hardware, software, & services), and region (the Americas, Europe, Asia-Pacific, and Rest of the World). Automation of distribution feeders in a power distribution network is essential today to achieve faultles …
- インテリジェント・プラットフォーム管理インターフェイス（IPMI）の世界市場予測（～2022年）The intelligent platform management interface market was valued at USD 1.20 Billion in 2015 and is expected to reach USD 3.10 Billion by 2022, at a CAGR of 13.2% between 2016 and 2022. The most significant factor driving the IPMI market is the rising demand for enhanced the server management, along with the reduced cost of ownership; also, increase in ICT spending and rising need for standardized …
- 世界の永久磁石市場：類型、用途、新開発、産業構造Permanent magnets are a vital part of modern life. They are found in or used to produce almost every modern convenience today, from speakers in mobile phones to the electric motors in hybrid cars; air conditioners and washing machines. Permanent magnets are used increasingly in technological applications, including traveling wave tubes, Hall Effect sensors, high temperature-resistant permanent mag …
- 中南米のバイオコントロール市場：バイオ殺虫剤、バイオ殺菌剤、バイオ 除草剤、バイオ殺線虫剤“Latin America biocontrol market is projected to grow at a CAGR of 15.14%” The Latin America biocontrol market was valued at USD 423.7 million in 2015, and is projected to grow at a CAGR of 16.5%, to reach USD 1,050.7 million by 2021. The market is driven by factors such as increasing awareness regarding biological crop protection products among the farmers in the region, developing economy, risin …
- Rhabdomyosarcoma：グローバル臨床試験レビューH2, 2013Rhabdomyosarcoma Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Rhabdomyosarcoma Global Clinical Trials Review, H2, 2013" provides data on the Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Rhabdomyosarcoma . It includes an overview of the trial numbers and their recruitment stat …
- アメリカの血液検査市場2014This report provides an overview of the US hematology market, including sales and market shares of leading instrument and consumable suppliers, as well as test volume and sales forecasts by market segment.Table of ContentsBusiness Environment 1. Health Care Expenditures 2. Cost Consciousness 3. Reimbursement 4. Industry Consolidation 5. Managed Care & …
- グローバル航空市場におけるトップ10企業分析Synopsis The ICD Research Global Top 10 Airline Companies: Company Guide is a crucial resource for anyone looking to gain information on the top companies in the global airline industry. Detailed company profile and SWOT analysis information is provided for all the leading companies who are ranked in order by total annual revenues generated. Deutsche Lufthansa AG United Continental Holdings, Inc. …
- 内視鏡の世界市場：フレキシブル内視鏡、硬性内視鏡、カプセル内視鏡The global endoscopy equipment market is segmented on the basis of product and application. By product, the market is categorized into endoscopes, visualization systems, other endoscopy equipment, and accessories. In 2015, the endoscopes segment is estimated to account for the larger share of the market and expected to grow at the fastest rate during the forecast period. The endoscopes market is f …
- 身体障害者向け車両の世界市場予測（～2027年）“Increasing population of aged people and various schemes provided by governments of various countries to disabled people are significant factors for the growth of the vehicles for disabled market globally.” The global vehicles for disabled market are estimated to grow from USD 2.6 billion in 2019 to reach USD 6.3 billion by 2027, at a CAGR of 11.7%. Increasing emphasis on providing equality to di …
- 無線LAN（Wi-Fi）チップセットの世界市場2016-2020About Wi-Fi Chipset Wi-Fi is a wireless technology used in networking. A Wi-Fi chipset is a system-on-chip (SoC) with all essential components required for wireless networking. Factors such as the growing integration between Wi-Fi and mobile networks, the development of smart-home technology, the proliferation of Wi-Fi-enabled mobile devices, the emergence of wearable technology, and increasing in …
- 水溶性フィルムの世界市場2016-2020About Water Soluble Films Water soluble films possess dimensional stability, reduced toxicity, have a high moisture and gas barrier, and are biodegradable, and easy to use. These advanced films are used to package goods like dyes, agrochemicals, laundry, electrical appliances, and linen bags. Agrochemical, water treatment chemicals, and detergent packages are key end-users of water soluble films. …
- 大気質管理システムの世界市場：屋内、周囲The global air quality control systems market was valued at $94,697.2 million in 2018, and is projected to reach $144,091.2 million by 2026, growing at a CAGR of 5.2%. Air quality is a vital aspect that needs to be conserved for both indoors and outdoors. The contaminated and harmful pollutants can result in adverse health effects. The industries such as cement manufacturing, chemical processing, …
